Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.

Details

Ressource 1Download: 13075_2017_Article_1372.pdf (591.86 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_DEF364FDE03C
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.
Journal
Arthritis research & therapy
Author(s)
Micheroli R., Hebeisen M., Wildi L.M., Exer P., Tamborrini G., Bernhard J., Möller B., Zufferey P., Nissen M.J., Scherer A., Ciurea A.
Working group(s)
Rheumatologists of the Swiss Clinical Quality Management Program
ISSN
1478-6362 (Electronic)
ISSN-L
1478-6354
Publication state
Published
Issued date
19/07/2017
Peer-reviewed
Oui
Volume
19
Number
1
Pages
164
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Few studies have investigated the impact of obesity on the response to tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA). The aim of our study was to investigate the impact of different body mass index (BMI) categories on TNFi response in a large cohort of patients with axSpA.
Patients with axSpA within the Swiss Clinical Quality Management (SCQM) program were included in the current study if they fulfilled the Assessment in Spondyloarthritis International Society (ASAS) criteria for axSpA, started a first TNFi after recruitment, and had available BMI data as well as a baseline and follow-up visit at 1 year (±6 months). Patients were categorized according to BMI: normal (BMI 18.5 to <25), overweight (BMI 25-30), and obese (BMI >30). We evaluated the proportion of patients achieving the 40% improvement in ASAS criteria (ASAS40), as well as Ankylosing Spondylitis Disease Activity Score (ASDAS) improvement and status scores at 1 year. Patients having discontinued the TNFi were considered nonresponders. We controlled for age, sex, HLA-B27, axSpA type, BASDAI, BASMI, elevated C-reactive protein (CRP), current smoking, enthesitis, physical exercise, and co-medication with disease-modifying antirheumatic drugs, as well as with nonsteroidal anti-inflammatory drugs in multiple adjusted logistic regression analyses.
A total of 624 axSpA patients starting a first TNFi were considered in the current study (332 patients of normal weight, 204 patients with overweight, and 88 obese patients). Obese individuals were older, had higher BASDAI levels, and had a more important impairment of physical function in comparison to patients of normal weight, while ASDAS and CRP levels were comparable between the three BMI groups. An ASAS40 response was reached by 44%, 34%, and 29% of patients of normal weight, overweight, and obesity, respectively (overall p = 0.02). Significantly lower odds ratios (ORs) for achieving ASAS40 response were found in adjusted analyses in obese patients versus patients with normal BMI (OR 0.27, 95% confidence interval (CI) 0.09-0.70). The respective adjusted ASAS40 OR in overweight versus normal weight patients was 0.62 (95% CI 0.24-1.14). Comparable results were found for the other outcomes assessed.
Obesity is associated with significantly lower response rates to TNFi in patients with axSpA.

Keywords
Adult, Anti-Inflammatory Agents/therapeutic use, Cohort Studies, Female, Humans, Male, Obesity/complications, Spondylarthritis/drug therapy, Treatment Outcome, Tumor Necrosis Factor-alpha/antagonists & inhibitors, Ankylosing spondylitis, Axial spondyloarthritis, Obesity, TNF inhibition
Pubmed
Web of science
Open Access
Yes
Create date
04/09/2017 9:50
Last modification date
20/08/2019 16:03
Usage data